Management of Significantly Reduced LDL-C After Atorvastatin Therapy
Assessment of Current Response
- The American College of Cardiology indicates that a 78% reduction in LDL-C from 178mg/dL to 40mg/dL represents an excellent response to atorvastatin 40mg daily, exceeding the expected 43-50% reduction typically seen with moderate-intensity statin therapy 1
- The American Heart Association recommends an optional very low LDL-C goal of <70mg/dL for high-risk patients, which is associated with greater cardiovascular risk reduction, and an LDL-C level of 40mg/dL falls below this goal 2
Evidence Supporting Maintenance of Current Therapy
- Clinical trials have demonstrated that intensive LDL-C lowering to levels well below 100mg/dL provides additional cardiovascular benefit compared to moderate lowering, with the American Heart Association supporting this approach 2, 3
- The PROVE-IT trial showed that achieving a median LDL-C of 62mg/dL with high-dose atorvastatin reduced major cardiovascular events by 16% compared to achieving 95mg/dL with pravastatin, as reported by the American Heart Association 2, 3
Safety Considerations for Very Low LDL-C
- The American Heart Association states that recent clinical trials have not identified significant adverse effects from LDL lowering per se, despite historical concerns about very low LDL-C levels 2
- In the PROVE-IT trial, high-dose atorvastatin was well-tolerated with no cases of severe myopathy (rhabdomyolysis) observed, according to the American Heart Association 3
Potential Pitfalls to Avoid
- The American College of Cardiology notes that the relative reduction in cardiovascular risk from statin therapy is related to the degree by which LDL-C is lowered 1
- The American Heart Association recommends avoiding unnecessary concern about very low LDL-C levels, as clinical trial data have not demonstrated harm from intensive LDL-C lowering 2